Shanghai Haixin Group Past Earnings Performance
Past criteria checks 5/6
Shanghai Haixin Group has been growing earnings at an average annual rate of 7.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 3.8% per year. Shanghai Haixin Group's return on equity is 4.9%, and it has net margins of 17.2%.
Key information
7.4%
Earnings growth rate
7.4%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 3.8% |
Return on equity | 4.9% |
Net Margin | 17.2% |
Next Earnings Update | 30 Oct 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Haixin Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 964 | 166 | 408 | 24 |
31 Mar 24 | 1,109 | 172 | 438 | 23 |
31 Dec 23 | 1,183 | 166 | 456 | 23 |
30 Sep 23 | 1,338 | 120 | 474 | 22 |
30 Jun 23 | 1,429 | 141 | 513 | 23 |
31 Mar 23 | 1,420 | 163 | 548 | 22 |
31 Dec 22 | 1,440 | 164 | 578 | 22 |
30 Sep 22 | 1,465 | 153 | 639 | 23 |
30 Jun 22 | 1,381 | 140 | 630 | 22 |
31 Mar 22 | 1,560 | 136 | 647 | 25 |
31 Dec 21 | 1,511 | 132 | 653 | 24 |
30 Sep 21 | 1,290 | 148 | 648 | 23 |
30 Jun 21 | 1,272 | 144 | 599 | 24 |
31 Mar 21 | 1,002 | 130 | 546 | 21 |
31 Dec 20 | 933 | 119 | 464 | 22 |
30 Sep 20 | 980 | 129 | 437 | 21 |
30 Jun 20 | 1,037 | 126 | 438 | 20 |
31 Mar 20 | 1,072 | 94 | 462 | 20 |
31 Dec 19 | 1,112 | 104 | 481 | 20 |
30 Sep 19 | 1,168 | 127 | 415 | 18 |
30 Jun 19 | 1,113 | 126 | 415 | 16 |
31 Mar 19 | 1,115 | 140 | 370 | 17 |
31 Dec 18 | 1,099 | 135 | 376 | 16 |
30 Sep 18 | 1,066 | 113 | 421 | 14 |
30 Jun 18 | 1,044 | 123 | 390 | 21 |
31 Mar 18 | 1,024 | 113 | 366 | 16 |
31 Dec 17 | 1,000 | 105 | 334 | 13 |
30 Sep 17 | 1,014 | 26 | 329 | 10 |
30 Jun 17 | 1,012 | 31 | 323 | 0 |
31 Mar 17 | 997 | 91 | 315 | 0 |
31 Dec 16 | 1,012 | 90 | 304 | 0 |
30 Sep 16 | 1,001 | 189 | 290 | 0 |
30 Jun 16 | 1,058 | 180 | 289 | 0 |
31 Mar 16 | 1,069 | 153 | 281 | 0 |
31 Dec 15 | 1,052 | 157 | 282 | 0 |
30 Sep 15 | 1,096 | 296 | 296 | 0 |
30 Jun 15 | 1,094 | 369 | 293 | 0 |
31 Mar 15 | 1,099 | 327 | 291 | 0 |
31 Dec 14 | 1,110 | 291 | 293 | 0 |
30 Sep 14 | 1,166 | 131 | 306 | 0 |
30 Jun 14 | 1,215 | 35 | 305 | 0 |
31 Mar 14 | 1,243 | 0 | 305 | 0 |
31 Dec 13 | 1,262 | 65 | 301 | 0 |
Quality Earnings: 900917 has high quality earnings.
Growing Profit Margin: 900917's current net profit margins (17.2%) are higher than last year (9.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 900917's earnings have grown by 7.4% per year over the past 5 years.
Accelerating Growth: 900917's earnings growth over the past year (18.2%) exceeds its 5-year average (7.4% per year).
Earnings vs Industry: 900917 earnings growth over the past year (18.2%) exceeded the Pharmaceuticals industry -0.6%.
Return on Equity
High ROE: 900917's Return on Equity (4.9%) is considered low.